Certara Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Certara's estimated annual revenue is currently $275.4M per year.(i)
  • Certara's estimated revenue per employee is $225,738
  • Certara's current valuation is $4.4B. (January 2022)

Employee Data

  • Certara has 1220 Employees.(i)
  • Certara grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$124.8M93834%$567.2M$2.2B
#2
$443.8M40037%$371.2M$2.8B
#3
$11.8M763%$3MN/A
#4
$1.2M6N/AN/AN/A
#5
$20.9M10430%$176.6MN/A
#6
$39060M6975615%$30 b$234.4B
#7
$108.1M538N/AN/AN/A
#8
$24.7M155N/AN/AN/A
#9
$1.1M13N/AN/AN/A
#10
$0.8M5N/AN/AN/A
#11
$2360M388710%$22.5M$10.7B
#12
$10.1M65N/AN/AN/A
#13
$7M45N/AN/AN/A
#14
$21.6M88-6%N/AN/A
#15
$0.1M4N/AN/AN/A
#16
$2.6M26N/AN/AN/A
#17
$71.6M462N/AN/AN/A
#18
$46.5M26414%$396M$424.9M
#19
$6.8M44N/AN/AN/A
#20
$0.4M8N/AN/AN/A

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara's solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. For more information, visit www.certara.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

1220

Number of Employees

$275.4M

Revenue (est)

11%

Employee Growth %

$4.4B

Valuation

N/A

Accelerator

Certara News

2022-04-20 - Global Computational biology Market 2022 Data Analysis and ...

Some of these market players include: Accelrys, Certara, Chemical Computing Group Inc, Compugen Ltd, Entelos, Genedata Ag, Insilico...

2022-04-20 - Certara and Chemaxon Announce Collaboration in Scientific ...

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and...

2022-04-13 - Analysts Expect Certara, Inc. (NASDAQ:CERT) Will Post ...

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and...

2021-11-10 - Certara Reports Third Quarter 2021 Financial Results - Form 8-K

Certara Reports Third Quarter 2021 Financial Results Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21 PRINCETON, N.J.-November 9, 2021-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for t ...

2021-11-10 - Certara Reports Third Quarter 2021 Financial Results

PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2021. Highlights: Revenue was $73.9 million, compared to $60.3 million in the third quarter of 2020, repre ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$272.6M13430%N/A
#2
$284.8M14030%N/A
#3
$290.7M1432N/AN/A
#4
$362.7M157036%N/A
#5
$314.2M1603N/AN/A